Literature DB >> 2776188

Sarcoplasmic ionic calcium concentration in neuroleptic malignant syndrome.

J R López1, V Sánchez, M J López.   

Abstract

The neuroleptic malignant syndrome (NMS) is an uncommon but serious adverse effect of antipsychotic medication. Similarities in the clinical picture, and muscle alterations, between NMS and susceptibility to malignant hyperthermia (MH) suggest common mechanisms underlying both disorders. Sarcoplasmic ionic calcium concentration ([Ca2+]i) was measured by means of Ca2+ selective microelectrodes in intact intercostal muscle fibers isolated from NMS patients and from subjects with no evidence of neuromuscular disease, who served as controls. The mean resting membrane potential and [Ca2+]i were -84 +/- 0.4 mV and 0.11 +/- 0.01 microM (mean +/- SEM) in the control subjects, while they were -84 +/- 0.6 mV and 0.51 +/- 0.02 microM in NMS muscle fibers. Only the difference in [Ca2+]i is significant (P less than 0.001). The incubation of control and NMS muscle bundles in dantrolene (10(-6) M) induced a reduction of [Ca2+]i to 0.06 +/- 0.01 microM and 0.20 +/- 0.04 microM respectively. These results show an alteration in sarcoplasmic ionic [Ca2+] in NMS muscle fibers, suggesting that a dysfunction in skeletal muscle plays some role in the pathogenesis of NMS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776188     DOI: 10.1016/0143-4160(89)90005-5

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  3 in total

Review 1.  Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael F Mazurek
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

Review 2.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

3.  Effects of chlorpromazine on excitation-contraction coupling events in fast-twitch skeletal muscle fibres of the rat.

Authors:  R Wagner; R H A Fink; D G Stephenson
Journal:  Br J Pharmacol       Date:  2004-01-19       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.